I take your points and agree about diversification, but Biota must also not drop the ball on their bread and butter (on what they understand best).
2012 should bring a nice injection of funds, so I believe FLUNET development should never stand still - neither should HRV or RSV.
"Too much patent overlap with Lani is a good reason to delay Flunet"
At the moment we are about to face 2-3 years patent underlap between Relenza and LANI, courtesy of poor planning.
Okay, we know LANI is patented till around 2027, but would you rather risk patent overlap versus a next gen, more effective drug (by Biota), or versus the chance of another competitor coming along with a better/more effective drug, I'd go with patent overlap.
Perhaps projecting forward 5-10 years and Biota won't be part of your investment strategies, but good planning goes to the heart of a well run company...the alternative is head in the sand stuff for other management and future holders to concern themselves about...
- Forums
- ASX - By Stock
- BTA
- vertex presentation jp morgan
vertex presentation jp morgan, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online